Lumenis Ltd., with U.S. operations in New York, NY and Santa Clara, CA, as well as global operations, announced that its IPL Quantum SR Intense Pulsed Light system will be used as part of a new multicenter Phase II clinical study. The study will be carried out at four locations in the U.S. by Dusa Pharmaceuticals Inc., with whom Lumenis has signed a development agreement.
IPL provides gentle, non-ablative treatments to remove sun-induced freckles, most benign brown pigments and redness caused by broken capillaries. Company executives said Lumenis was the first to introduce the IPL technology to the aesthetic market.
The multicenter study will focus on rejuvenation of photodamaged skin. Published reports from leading physicians indicate that Dusa’s drug Levulan, when used in conjunction with the IPL Quantum SR, may optimize non-ablative photorejuvenation of damaged skin, according to executives.
“As the developer of IPL and the continued leader in the creation of the most innovative IPL systems, Lumenis was the logical choice as the only IPL partner with Dusa in these very important clinical studies,” said Dr. Mitchell Goldman, co-author of one of the published reports. “We expect these studies to clearly demonstrate the significant enhancing effect of Levulan on skin treatments using photorejuvenation. As a result, millions of patients worldwide will benefit from the efforts of these two industry leaders.”
The study will seek to demonstrate that treatment is improved when IPL is used in conjunction with Levulan. More info: www.lumenis.com.